Medeon Biodesign (6499.TWO) Earnings Analysis
Medeon Biodesign (6499.TWO) next reports earnings on 2026-08-12, consensus EPS -1.8 TWD. Last quarter (2026-05-08) it beat with EPS -1.26 TWD vs -1.76 TWD est (+28.4%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E -9.68.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 6499.TWO next report earnings?
| Next earnings date | 2026-08-12 |
|---|---|
| Consensus EPS estimate | -1.8 TWD |
| Revenue estimate | 0.12B |
6499.TWO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-08 | -1.26 TWD | -1.76 TWD | +28.4% | Beat |
| 2026-03-09 | -1.48 TWD | -1.49 TWD | +0.7% | Beat |
| 2025-11-06 | -1.87639 TWD | -1.91115 TWD | +1.8% | Beat |
| 2025-08-07 | -1.93 TWD | -1.695 TWD | -13.9% | Miss |
| 2025-03-14 | -2.26528 TWD | n/a | n/a | n/a |
| 2024-11-11 | -2 TWD | n/a | n/a | n/a |
Beat rate: 3/4 (75%) over reported quarters with consensus data.
6499.TWO valuation and analyst view
| Trailing P/E | -9.68 |
|---|---|
| Trailing EPS | -6.50692 TWD |
| Price / book | 4.51 |
| Dividend yield | 0.00% |
| Market cap | 6.16B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Medeon Biodesign (6499.TWO)'s next earnings date?
Medeon Biodesign is next scheduled to report on 2026-08-12, with a consensus EPS estimate of -1.8 TWD and revenue estimate of 0.12B.
Did 6499.TWO beat earnings last quarter?
In its 2026-05-08 report, 6499.TWO posted EPS of -1.26 TWD versus a -1.76 TWD estimate — a beat of 28.4%.
What is 6499.TWO's earnings track record?
Over the last 4 reported quarters with consensus data, 6499.TWO beat estimates 3 times (75%).
What is 6499.TWO's current P/E ratio and EPS?
6499.TWO trades at a trailing P/E of -9.68 on trailing EPS of -6.506922544022003 TWD.
What do analysts rate 6499.TWO?
6499.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.